TY  - JOUR
AU  - Mora, J
AU  - Castañeda, A
AU  - Perez-Jaume, S
AU  - Lopez-Pousa, A
AU  - Maradiegue, E
AU  - Valverde, C
AU  - Martin-Broto, J
AU  - Garcia Del Muro, X
AU  - Cruz, O
AU  - Cruz, J
AU  - Martinez-Trufero, J
AU  - Maurel, J
AU  - Vaz, M A
AU  - de Alava, E
AU  - de Torres, C
PY  - 2017
DO  - 10.1038/bjc.2017.252
UR  - http://hdl.handle.net/10668/11488
T2  - British journal of cancer
AB  - First Spanish trial of Ewing sarcoma (ES) including adults and children with the aim to test the efficacy of Gemcitabine and Docetaxel (G/D) in newly diagnosed high-risk (HR) patients. This was a prospective, multicentric, non-randomised, open study...
LA  - en
PB  - Nature Publishing Group
KW  - gemcitabine
KW  - docetaxel
KW  - Ewing sarcoma
KW  - adolescent and young adult sarcomas
KW  - minimal residual disease management
KW  - Adolescent
KW  - Adult
KW  - Age Factors
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Bone Neoplasms
KW  - Child
KW  - Child, Preschool
KW  - Deoxycytidine
KW  - Disease-Free Survival
KW  - Docetaxel
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Odds Ratio
KW  - Prognosis
KW  - Prospective Studies
KW  - Sarcoma, Ewing
KW  - Spain
KW  - Survival Rate
KW  - Taxoids
KW  - Gemcitabine
TI  - GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS).
TY  - research article
VL  - 117
ER  -